ESR1 and breast carcinoma: For instance, hsa‐miR‐335‐5p was shown to inhibit tumour re‐initiation and metastasis [90], and to synergize with hsa‐miR‐335‐3p to inhibit oestrogen receptor alpha expression and promote tamoxifen resistance in breast cancer cells [91].